A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
This research study is investigating a new medication, mitapivat, for individuals living with alpha or beta thalassemia who rely on frequent blood transfusions. The main goal is to determine if mitapivat can decrease the number of blood transfusions these patients need over time. Participants will receive either mitapivat or a placebo (a dummy drug) to see if the new medicine works and if it's safe. Thalassemia is a blood condition where the body doesn't produce enough healthy red blood cells, often leading to anaemia and requiring transfusions. This study is in its advanced stages, meaning it’s already shown some promise in earlier testing. Researchers want to understand if mitapivat could be a new treatment option to improve the lives of people affected by this condition.
Överblick
Resultat
Resultat från denna studie
Publicerad May 2025Resultaten har publicerats för denna studie.
Vad handlar denna studie om?
This study is testing a new medicine called mitapivat for people who have a specific type of blood condition called thalassemia. Thalassemia means your body can't make enough healthy red blood cells, which carry oxygen around your body. Because of this, many people with severe thalassemia, especially those with what's called 'transfusion-dependent' alpha or beta thalassemia, need regular blood transfusions. These transfusions can make life difficult and have their own risks over time.
The main idea behind this study is to see if mitapivat can help people with thalassemia reduce how often they need these blood transfusions. Some participants will receive the actual medicine, while others will get a placebo, which looks like the medicine but contains no active ingredients. This helps researchers fairly compare the new drug's effects. Knowing if a medicine can lessen the need for transfusions is very important because it could greatly improve daily life for people with thalassemia and reduce the associated medical burdens.
This is a Phase 3 study, which means it's a large, in-depth trial involving many participants. Medicines reach this stage after showing encouraging results in earlier, smaller studies. The detailed description states that 171 people were given mitapivat and 87 were given the placebo. This setup allows the researchers to gather strong evidence about the medicine's effectiveness and safety, helping them decide if it could become a widely available treatment in the future. The ultimate aim is to find better ways to manage thalassemia and improve the health and well-being of those affected.
Viktiga punkter
- This study is testing a new medicine for severe thalassemia.
- It aims to reduce the need for blood transfusions.
- Participants will receive either the new medicine or a dummy treatment.
- It's a large study, meaning the medicine has shown promise in earlier tests.
- Careful monitoring of health and safety will be provided.
- Deltagande är frivilligt, och du kan dra dig ur när som helst.
Vem kan vara berättigad?
To join this study, you would need to be at least 18 years old and have a confirmed diagnosis of alpha or beta thalassemia based on genetic tests. A key requirement is that your thalassemia is considered 'transfusion-dependent'. This means you've needed between 6 and 20 units of red blood cells and haven't gone longer than six weeks without a transfusion in the six months before the study starts. If you're currently taking a medicine called hydroxyurea, your dose must have been stable for at least 16 weeks before you can join.
There are also some reasons why you wouldn't be able to join. For example, if you are pregnant or breastfeeding, or if you've recently had other specific treatments like gene therapy or a bone marrow transplant. You also wouldn't be eligible if you have certain other serious health issues, like active heart or lung disease, or a recent history of certain cancers. The study also cannot include those who have recently used other specific thalassemia medications like luspatercept or other blood-stimulating agents.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Är du 18 år eller äldre?
- Do you have a confirmed diagnosis of alpha or beta thalassemia?
- Do you need regular blood transfusions for your thalassemia (6-20 units in the last 6 months, and no longer than 6 weeks without a transfusion)?
- Är du inte gravid eller ammar?
- Have you spoken to your doctor about this study and understand the requirements?
Vad innebär deltagande?
If you decide to take part in this study, you will be given either the study medicine, mitapivat, or a placebo (a dummy pill). You won't know which one you're receiving, and neither will your local study team, until the study is over. You'll have regular visits to the hospital or clinic where doctors will monitor your health, perform blood tests, and check how often you need blood transfusions. These visits are important to track the medicine's effects and ensure your safety. The study involves taking the medication for a set period, and there will be follow-up appointments even after you stop taking the study drug to see how you're doing. The total duration of your participation, including follow-up, will be explained in detail by the study team.
Potentiella risker och fördelar
Platser (75)
- Phoenix BarnsjukhusVerifierat postnummerPhoenix, USA
- San Diego Hospital, UC San Diego HealthVerifierat postnummerLa Jolla, USA
- Children's Hospital OaklandVerifierat postnummerOakland, USA
- Stanford MedicineVerifierat postnummerPalo Alto, USA
- Boston BarnsjukhusVerifierat postnummerBoston, USA
- Barnsjukhuset i MichiganVerifierat postnummerDetroit, USA
- Weill Cornell Medical CenterVerifierat postnummerNew York, USA
- Duke University Medical CenterVerifierat postnummerDurham, USA
- Penn Medicine - University of Pennsylvania Health SystemVerifierat postnummerPhiladelphia, USA
- Seattle Cancer Care Alliance, University of WashingtonVerifierat postnummerSeattle, USA
- Hospital Das Clínicas da Faculdade de Medicina de Ribeirão Preto - USPVerifierat postnummerRibeirão Preto, Brazil
- GSH Banco de Sangue de São PauloVerifierat postnummerSão Paulo, Brasilien
Vanliga frågor
What is thalassemia?
Thalassemia is a genetic blood disorder where your body doesn't produce enough healthy red blood cells, leading to anaemia and other health issues.
What does 'transfusion-dependent' mean?
It means you regularly need blood transfusions because your body can't make enough red blood cells on its own to stay healthy.
Vad är en placebo?
A placebo is a substance or treatment that looks exactly like the study medicine but doesn't contain any active ingredients. It's used for comparison.
Why can't I be pregnant or breastfeeding?
For your safety and the safety of your baby, pregnant or breastfeeding individuals are typically not included in drug trials because medicines can affect a developing baby or be passed through breast milk.
Will I feel better right away?
There's no guarantee the medicine will work, or how quickly. The study aims to see effects over time, and your health will be closely monitored.
Hur du får reda på mer
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.